**Chapter 3**

*Perioperative Care for Organ Transplant Recipient*

meta-analysis. Transplantation.

[112] Velidedeoglu E, Cavaille-Coll MW, Bala S, Belen OA, Wang Y, Albrecht R. Summary of 2017 FDA Public Workshop: Antibody-mediated rejection in kidney transplantation. Transplantation. 2018;**102**(6):e257-ee64

[113] Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann

[114] Sautenet B, Blancho G, Buchler M, Morelon E, Toupance O, Barrou B, et al. One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebocontrolled trial. Transplantation.

[115] Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. American Journal of Transplantation. 2004;**4**(6):996-1001

[116] Morris PJ. Transplantation—A medical miracle of the 20th century. The New England Journal of Medicine.

2004;**351**(26):2678-2680

M, et al. A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection. Journal of the American Society of Nephrology.

2018;**29**(2):591-605

2016;**100**(2):391-399

2018;**102**(4):557-568

**36**
